company background image
524824 logo

Bal Pharma BSE:524824 Stock Report

Last Price

₹103.33

Market Cap

₹1.6b

7D

3.0%

1Y

-12.8%

Updated

14 Jun, 2025

Data

Company Financials

Bal Pharma (524824) Stock Overview

Manufactures and markets pharmaceutical formulations and active pharmaceutical ingredients (APIs) in India and internationally. More details

524824 fundamental analysis
Snowflake Score
Valuation2/6
Future Growth0/6
Past Performance3/6
Financial Health3/6
Dividends3/6

524824 Community Fair Values

Create Narrative

See what others think this stock is worth. Follow their fair value or set your own to get alerts.

Bal Pharma Limited Competitors

Price History & Performance

Summary of share price highs, lows and changes for Bal Pharma
Historical stock prices
Current Share Price₹103.33
52 Week High₹157.90
52 Week Low₹76.30
Beta0.20
1 Month Change6.75%
3 Month Change25.46%
1 Year Change-12.76%
3 Year Change9.46%
5 Year Change133.51%
Change since IPO923.07%

Recent News & Updates

Recent updates

Shareholder Returns

524824IN PharmaceuticalsIN Market
7D3.0%1.4%-0.9%
1Y-12.8%13.0%-0.3%

Return vs Industry: 524824 underperformed the Indian Pharmaceuticals industry which returned 13% over the past year.

Return vs Market: 524824 underperformed the Indian Market which returned -0.3% over the past year.

Price Volatility

Is 524824's price volatile compared to industry and market?
524824 volatility
524824 Average Weekly Movement9.8%
Pharmaceuticals Industry Average Movement6.5%
Market Average Movement6.6%
10% most volatile stocks in IN Market9.3%
10% least volatile stocks in IN Market4.4%

Stable Share Price: 524824's share price has been volatile over the past 3 months compared to the Indian market.

Volatility Over Time: 524824's weekly volatility (10%) has been stable over the past year, but is still higher than 75% of Indian stocks.

About the Company

FoundedEmployeesCEOWebsite
1987868Shailesh Siroyawww.balpharma.com

Bal Pharma Limited, together with its subsidiaries, manufactures and markets pharmaceutical formulations and active pharmaceutical ingredients (APIs) in India and internationally. The company offers prescription drugs, generics, OTC products, intravenous infusion products, and bulk drugs. It also provides anti-infectives, pain management, respiratory care, and women's health products under the Aziwin, Ebay, Balvibe, MNF, Ocium, and Monogesic Plus Gel brands; diabetic care products under the Diabend and Diabend M Group brands; herbal/ayurvedic preparations targeting conditions, such as prostate enlargement, renal calculi, male infertility, and women health, etc. under the Stonex, Ashwamed, Prostowin, Suswas, Menoleap, and Ayursulin brands; anti-hypertensive, anti-lipidemic, and anti-obese products; skin care and bone health products; and cardiac care products under the Secremet and Servace brands.

Bal Pharma Limited Fundamentals Summary

How do Bal Pharma's earnings and revenue compare to its market cap?
524824 fundamental statistics
Market cap₹1.63b
Earnings (TTM)₹72.15m
Revenue (TTM)₹3.03b
22.6x
P/E Ratio
0.5x
P/S Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
524824 income statement (TTM)
Revenue₹3.03b
Cost of Revenue₹1.58b
Gross Profit₹1.45b
Other Expenses₹1.38b
Earnings₹72.15m

Last Reported Earnings

Mar 31, 2025

Next Earnings Date

n/a

Earnings per share (EPS)4.57
Gross Margin47.90%
Net Profit Margin2.38%
Debt/Equity Ratio194.3%

How did 524824 perform over the long term?

See historical performance and comparison

Dividends

1.2%
Current Dividend Yield
26%
Payout Ratio

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/06/14 21:33
End of Day Share Price 2025/06/13 00:00
Earnings2025/03/31
Annual Earnings2025/03/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Bal Pharma Limited is covered by 0 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.